---
document_datetime: 2025-07-04 18:10:07
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/strimvelis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: strimvelis-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.4157574
conversion_datetime: 2025-12-26 18:31:10.430578
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Strimvelis

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproduct lifecycleprocedures,you mayneedtoalsorefertoEPAR-Proceduralsteps taken andscientific informationafterauthorisation(archive).

| Applicationnumber   | Scope                                  | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|----------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| VariationtypeIA/    | This was an application for a group of | 04/07/2025                          |                                          | Annex II and                    |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282063                    | variations. B.III.1.bEuropeanPharmacopoeial TSE Certificate ofsuitabilityfor an active substance/startingmaterial/reagent/ intermediate/or excipient - B.III.1.b.3 Updated certificate from an already approved manufacturer-Accepted A.ADMINISTRATIVECHANGES-A.7 Deletion ofmanufacturingsitesfor an active substance, intermediate or finished product, packagingsite,manufacturerresponsiblefor batchrelease,sitewherebatchcontrol takes place,orsupplierof astartingmaterial, reagent orexcipient(when mentioned in the dossier)*- Accepted   |            | PL                               |
|--------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|----------------------------------|
| Variation typeIB / EMA/VR/0000252655 | B.1I.g.5Implementationofchangesforeseen in an approved change management protocol - B.I1.g.5.c Implementation of a change for a biological/immunological medicinal product-Accepted                                                                                                                                                                                                                                                                                                                                                               | 26/03/2025 | SmPC, Annex II, Labelling and PL |